Interleukin-6 (IL-6) inhibits the growth of melanocytes and of early stage melanoma cells, but not that of advanced melanoma cells. The in vitro IL-6 response can be restored in the highly metastatic melamona B16-F10.9 by addition of recombinant soluble IL-6 receptor a-chain (sIL-6R). The F10.9 cells then undergo irreversible growth-arrest and show increased adherence with changes from epithelioid to spindleoid morphology. The sIL-6R is required for IL-6 to induce a sustained activation of the various Stat transcription factors which bind to speci®c IL-6 inducible enhancers. The sIL-6R and IL-6 combination causes an increase in the level of the anti-oncogenic transcription factor IRF-1 protein and DNA-binding, which remain elevated for 24 h. The promoter activity of the anti-oncogenic p21/Waf-1/Cip-1 gene is induced and accumulation of the p21 protein is observed. These results illustrate the potent agonist activity of sIL-6R on molecular pathways which could mediate the growth-arrest and dierentiation of the metastatic melanoma cells. Previously observed antimetastatic eects of IL-6 therapy in mice bearing F10.9 tumors may be at least partly due to direct growth inhibition and dierentiation elicited by sIL-6R present in biological¯uids.
Introduction
Melanocytes or cells from early stages of human melanomas (radial growth or early vertical growth phases) are inhibited in their growth by or by Transforming Growth Factor-b (TGF-b) (Lu et al., 1992) . On the other hand, cells from advanced melanoma at metastatic stages often lose the antiproliferative eect of IL-6, and acquire an autocrine production of IL-6 (Colombo et al., 1992; Kerbel, 1993, 1994) . One mechanism of this altered IL-6 response may be that autocrine IL-6 acts as growth promoter inside cells from late stage melanoma, since antisense IL-6 inhibits growth (Lu and Kerbel, 1993 ) whereas antibodies to IL-6 do not (Silvani et al., 1995; Ganapathi et al., 1996) . Another mechanism may be loss of functional receptor, since production of IL-6 by IL-6 cDNA transfection leads to down regulation of the IL-6 Receptor (receptor a-chain or gp80) and to resistance against IL-6 which can be overcome by exogenous addition of soluble Receptor (sIL-6R) (Mackiewicz et al., 1992) . However, while restoration by sIL-6R was reported in IL-6-transfected early melanoma cells, it was not observed until now in melanoma cells which were spontaneously resistant to IL-6 (Silvani et al., 1995) . We study a highly metastatic F10.9 melanoma cells, derived from the spontaneous B16 melanoma of C57B1/6 mice, whose growth in vitro is completely insensitive to IL-6 but on which IL-6 has a marked antitumoral eect in vivo (Katz et al., 1993a) . Thus, IL-6 injections to mice abrogated lung metastastes when the F10.9 cells were given intravenously or in mice carrying footpad tumors, even when IL-6 therapy was initiated only following resection of the primary tumor (Katz et al., 1993a; Revel et al., 1995) . We show here that the in vitro sensitivity of these metastatic melanoma cells to IL-6 can be restored by sIL-6R and that the melanoma cells then undergo irreversible growth-arrest and morphological dierentiation.
Soluble forms of IL-6R are natural cell products, found in urine (Novick et al., 1990) and circulating in the blood (Gaillard et al., 1993; Frieling et al., 1994) . These molecules have the characteristic to be potent agonists of IL-6 not only in cells defective in gp80 (Taga et al., 1989; Hibi et al., 1990) but also in cells with abundant IL-6 binding sites (Novick et al., 1992) . This unusual property is due to the fact that even without the intracytoplasmic IC domain, sIL-6R acts with IL-6 to trigger the dimerization of the gp130 breceptor chain mediating signal transduction (Murakami et al., 1993) . The active IL-6 receptor assembly on cells is actually a hexameric structure with two IL-6R, two gp130 and two IL-6 ligands (Ward et al., 1994; Paonessa et al., 1995) in which the cytokine-receptor domain of IL-6R makes two types of interactions with gp130, both being necessary for biological activity (Halimi et al., 1995) . The IL-6R chain is speci®c to IL-6 whereas LIF, OSM, CNTF, IL-11 only share the gp130 component .
Downstream pathways of signal transduction and gene modulation by IL-6 which are activated by gp130 dimerization include activation of tyrosine kinases Jak1, Jak2 and Tyk2 (Guschin et al., 1995; Narazaki et al., 1994; Stahl et al., 1994) , but also of Btk, Tec and Fes (Matsuda et al., , 1995 , as well as activation of MAP kinase-dependent pathways (Akira et al., 1995) . Several Signal Transducer and Transcriptional Activator (Stat) proteins are phosphorylated in response to IL-6 including gp130-bound Stat3/APRF (Akira et al., 1994; Harroch et al., 1994b; Zhong et al., 1994; Stahl et al., 1995) as well as Stat1 (Harroch et al., 1994a,b; Zhong et al., 1994) and Stat5b (Ripperger et al., 1995) . The various Stat proteins compose nuclear transcription complexes of diering anities for a group of enhancers designated as palindromic Inter-feron Regulated Elements (pIRE) since they are also activated by Interferons (Sims et al., 1993; Harroch et al., 1994a,b) . Typical genes with pIRE enhancers are the transcription factor IRF-1 and the acute-phase protein a2-macroglobulin (a2M) which are induced by IL-6 in dierent cell types (Harroch et al., 1994a; Wegenka et al., 1994) .
IRF-1 is a transcription factor which has cytostatic (Harada et al., 1993) and anti-oncogenic activities (Tanaka et al., 1994) and is involved in cell apoptosis (Tamura et al., 1995; Taniguchi et al., 1995) . Increases in the ratio of IRF-1 protein and DNA binding activity over those of its inhibitor IRF-2, correlate with downregulation of cell growth Revel et al., 1995 for reviews) . In this study, we also examined the inhibitor of cyclin-dependent kinases p21/Waf-1/Cip-1 (El-Deiry et al., 1993; Harper et al., 1993) as another candidate tumor suppressor gene . Increases in p21/Waf-1 mRNA have been observed in M1 myeloleukemic M1 cells undergoing terminal dierentiation induced by IL-6 (Steinman et al., 1994) . Since this gene product is the melanoma dierentiation antigen mda-6 , it may be involved in the regulation of melanoma cell growth and dierentiation elicited by the IL-6+sIL-6R combination.
Results
Soluble IL-6R restores growth inhibition by IL-6 in F10.9 melanoma cells
The growth of F10.9 cells in vitro was unaected by IL-6 alone but became strongly inhibited when sIL-6R was added (Figure 1 ). Interestingly the eect of sIL-6R was more pronounced with excess IL-6 than with limiting amounts of the ligand. At high IL-6, maximal inhibition could be obtained with 150 ng/ml of sIL-6R (Figure 1 ). Under these conditions, counting live cells showed 87% inhibition at day three of culture. We studied whether the IL-6+sIL-6R combination exerts a reversible growth-inhibition or a terminal growtharrest. Since the F10.9 multiply by over threefold every day, a reversible eect should no more be apparent 2 ± 3 days after removal of the cytokines. However, cells treated 2 and 3 days by IL-6+sIL-6R and then changed to fresh medium still showed inhibitions of 50% and 70% respectively at day 5 (Table 1) . When treated only 1 day, most of the cells resumed their growth after removal of IL-6+sIL-6R. Therefore, a large fraction of the cells undergo irreversible growth-arrest between 2 to 3 days.
A marked morphological change became apparent in the F10.9 melanoma cells treated with the IL-6+sIL-6R combination (Figure 2, panel 4) . After two days, The cells were cultured in triplicates (2000 cells/well/0.2 ml medium) without or with IL-6 (40 ng/ml) and sIL-6R (500 ng/ml, BlueSepharose puri®ed). Cells were either kept continuously in the same conditions or washed after the indicated treatment time and refed with normal medium. Cells were ®xed 5 days after seeding and stained with Crystal Violet (see Materials and methods). Without IL-6 and sIL-6R, cells reached con¯uency within 3 days Figure 1 Eect of IL-6 and sIL-6R concentrations on melanoma F10.9 cell growth. Cells seeded at 2000 cells/well in 96-well plates were cultured for 5 days with the indicated amounts of IL-6 and sIL-6R. After staining with crystal violet, colour was extracted and OD at 570 nm was measured. Percent growth inhibition was calculated versus untreated wells 1. NT 2. IL-6 3. sIL-6R 4. IL-6+sIL-6R Figure 2 Morphological dierentiation of melanoma F10.9 cells by IL-6 and sIL-6R. After 4 days of culture with indicated additions (IL-6, 40 ng/ml; sIL-6R DVal, 1 mg/ml), the cells were ®xed with glutardialdehyde and stained with crystal violet (see Materials and methods). Magni®cation 6400 the cells started to show elongated dendrite-like extensions and¯at, more adherent, shapes which are reminiscent of the spindleoid dierentiation in fetal melanocytes (Houghton et al., 1982) . At 4 days, over 90% of the cells showed the spindleoid appearance. This morphological change was not observed with IL-6 alone or with sIL-6R alone ( Figure 2 , panels 2,3). The change in shape and the irreversible growth-arrest produced by IL-6 plus sIL-6R resemble the terminal dierentiation induced by Mezerein plus IFN-b in other melanoma cells (Fisher et al., 1985) , a process which is accompanied by modi®cations of cytoskeleton-bound surface adhesion proteins . On the other hand, murine IFN-g which also markedly inhibited growth of F10.9 cells, failed to induce these typical morphological changes (not shown). Another cytokine acting through gp130 such as Leukemia
Inhibitory Factor (LIF) tested at up to 100 ng/ml did not inhibit F10.9 growth (not shown). Spliced sIL-6R, which is a normal product of human cells resulting from translation of the alternatively spliced mRNA skipping the exon of the transmembrane domain (Oh et al., 1996) was active to inhibit F10.9 growth when added to IL-6, and monoclonal antibody 34.4 against human sIL-6R (Novick et al., 1991) abrogated the eect of the dierent recombinant sIL-6R on the F10.9 cells (not shown).
sIL-6R is required for activation of STAT transcription complexes in the F10.9 cells
Signal transduction in the F10.9 melanoma cells was studied by examining the formation of transcription complexes on the pIRE enhancer sequences of the PIRFA   III   ns   2h  4h  1d  3d  2h  4h  1d  3d  1h  2h  4h  12h  1d  3d  2h  4h  1d  3d  1h  2h  4h  12h  1d 3d
Figure 3 IL-6 and sIL-6R requirement for Stat factor binding to pIRE DNA elements. EMSA performed with 3 mg proteins of nuclear extracts from F10.9 cells treated for indicated times by IL-6 (80 ng/ml) without or with sIL-6R DVal (1 mg/ml).
5'
32 P-labelled ds-oligonucleotides were (a) pIRE/IRF-1 or (b, c) pIRE/a2M, and analysis of the DNA-protein complexes on non-denaturing gels was as described (Harroch et al., 1994a) . In (c), sIL-6R with the additional Blue Sepharose (bs) puri®cation step was used IRF-1 and a2-macroglobulin (a2M) genes (Figure 3) . With pIRE/IRF-1 the predominant DNA-protein band is pIRF-A, previously shown to contain Stat3 in complex with another 91 kDa protein and with a smaller 46 kDa protein (Harroch et al., 1994b) . The pIRF-A complex was strongly induced in F10.9 cells treated with IL-6 plus sIL-6R but only very weakly in cells treated by IL-6 alone ( Figure 3a) . sIL-R alone had also no eect (Figure 3c ). The faster migrating pIRE/ IRF-1 complex III, formed by Stat1/Stat1 homodimers (Harroch et al., 1994b; Zhong et al., 1994) , similarly required both IL-6 and sIL-6R (Figure 3a) . In addition to pIRF-A and Stat1/Stat1, the pIRE/a2M enhancer probe also visualizes complex I and II respectively formed by Stat3 homodimers and Stat1/Stat3 heterodimers (Zhong et al., 1994; Harroch et al., 1994b) . The four types of Stat factor complexes were seen to be induced by IL-6 plus sIL-6R when pIRE/a2M was used (Figure 3b ). The time course shows that treatment of F10.9 cells by IL-6 plus sIL-6R produces a sustained activation of Stat factors from 1 h to 1 day and even to 3 days for some complexes (Figure 3a and b) . The kinetic dierences between the two enhancer probes and the dierent Stat complexes were reproducible, notably the biphasic induction pattern of the Stat1 homodimers (complex III). This may indicate differential activations of the proteins forming these complexes and possibly competition for the same DNA binding sites.
Transcriptional activation involves, in addition to tyrosine phosphorylation and DNA binding of the Stat factors, also additional modi®cations such as serine phosphorylation Zhang et al., 1995) . Transcriptional activation was assayed by transfection of the F10.9 cells with Luciferase reporter genes containing six repeats of the pIRE/a2M enhancer fused to an SV40 promoter sequence (Harroch et al., 1994a) . Cells treated 24 h after transfection, showed induced expression of Luciferase at 5 h and more so at 20 h after IL-6 and sIL-6R addition, whereas IL-6 alone or sIL-6R alone had no eect on expression of this pIRE-controlled gene (Figure 4a ).
Induction of IRF-1 protein and DNA-binding activity
Modulation of IRF-1 in the F10.9 cells undergoing the IL-6-induced growth-arrest was evaluated by the steady-state level of IRF-1 protein, its DNA-binding activity as well as by the ratio of IRF-1 to IRF-2 which correlates with growth inhibition (Taniguchi et al., 1995 for review; Harroch et al., 1994a) . Immunoblots of F10.9 nuclear proteins with anti-IRF-1 antibodies showed that the IRF-1 protein level increased to a maximum at 60 min after addition of IL-6+sIL-6R (Figure 5b) . From 1.5 to 24 h, the level of IRF-1 remained elevated at a substained level (as compared internally to the 94 kDa band of the blot), but was back to basal level at day 3. The IRF-2 protein was assessed on similar blots reacted with anti-IRF-2 antibodies (Figure 5a ). In addition to the non-speci®c cross-reacting 94 kDa band, anti-IRF-2 reacted with two bands of 55 and 48 kDa, which represent dierent forms of IRF-2 diering by phosphorylation as shown by phosphase treatment (Harroch S and Chebath J, unpublished data) . The 55 kDa IRF-2 band was reduced by half at 24 h and by fourfold at 3 days (as normalized to the 94 kDa band). The decrease in some of the IRF-2 forms at a time when IRF-1 is still elevated may further contribute to growth inhibition.
The DNA binding activity of IRF-1 was measured by EMSA with the C13 probe (Figure 6 ; see Materials and methods). Since IRF-2 also binds to C13 DNA, we ®rst treated the nuclear extracts with anti-IRF-2 which leaves only the IRF-1 complex (and a supershifted band). Under these conditions, an increase in IRF-1 DNA-binding activity was clearly seen in the F10.9 melanoma cells treated by the IL-6+sIL-6R combination from 1 to 24 h (Figure 6 ). This increased binding correlates with the IRF-1 protein level. Treatment with IL-6 alone did not produce a signi®cant increase in IRF-1 DNA-binding (Figure 6 ), and sIL-6R alone had no eect (not shown). Thus, the irreversible growtharrest of the F10.9 cells occurring about 2 days after treatment (Table 1 ) follows in time an increase of IRF-1 activity in the cells.
Induced expression of the cyclin-dependent kinase inhibitor p21/Waf-1 gene
To investigate whether the p21/Waf-1/Cip-1 gene promoter was activated during the treatment of F10.9 cells by IL-6 and sIL-6R, we used a Luciferase reporter gene under the control of the 2.4 kb genomic DNA fragment comprising the p21 gene promoter and part of the ®rst exon (El-Deiry et al., 1993) . The expression was increased by 2 ± 3 fold at 24 to 48 h after addition of IL-6+sIL-6R, but not by IL-6 alone (Figure 4b) . At 5 h, activation of the p21/Waf-1 gene promoter was not yet detectable by this assay.
The level of the p21/Waf-1 protein as measured in immunoblots of F10.9 cell proteins extracted by SDS was induced by the IL-6+sIL-6R combination ( Figure  7) . The basal level of the protein tended to decrease with time after seeding of the cells, and this trend was seen also in the treated cells. At all time points, the data (quanti®ed by comparison with another protein bc12) showed that the p21/Waf-1 level was at least twofold higher when sIL-6R was added than when the cells were treated with IL-6 alone ( Figure 7) . The increase over the basal level of the protein which is produced by IL-6 alone is surprising in view of the very small transcriptional eect of IL-6 alone on the p21/ Waf-1 gene (Figure 5b) , and suggests that some posttranscriptional modulation may also contribute to the p21/Waf-1 protein accumulation. This is further suggested by the increased protein level at early times (0.5 and 2 h after IL-6+sIL-6R) when the transcriptional induction was not yet apparent. Nevertheless, the eects of IL-6 with sIL-6R on growth and dierentiation of the F10.9 melanoma cells appear to correlate with a transcriptional eect on the p21/Waf-1 gene and with the higher accumulation of the protein in the cells.
Discussion
The growth-inhibitory eect of IL-6 on melanocytes and early stage melanomas is often lost in more malignant melanoma cells (Lu and Kerbel, 1994) . The B16-F10.9 melanoma cells are highly metastatic in mice and resistant to IL-6 in vitro (Katz et al., 1993a) but this work shows that the resistance can be overcome by the addition of soluble forms of IL-6 receptor protein gp80. The IL-6+sIL-6R combination induces in these cells an irreversible growth-arrest and a morphological dierentiation resembling the spindleoid dierentiation of fetal melanocytes. sIL-6R elicits changes in signaling and in gene expression.
The F10.9 cells have low but detectable levels of IL-6 binding (Katz et al., 1993a) . IL-6 alone produces little activation of the various tyrosine-phosphorylated Stat transcriptional eectors. Addition of the sIL-6R not only increases the intensity of the Stat protein-DNA complexes but also produces an activation pattern of unusual duration. For example, the largest complex pIRF-A was seen from 1 ± 24 h with the pIRE/IRF-1 enhancer and from 4 ± 72 h with pIRE/ a2M. pIRF-A contains Stat3, another subunit of similar size (possibly Stat5b also activated by IL-6 as shown by Ripperger et al., 1995) and an additional DNA binding factor p46 (Harroch et al., 1994b) . The diering kinetics with the two pIRE sequences may re¯ect respective anities, changes in protein composition or Stat modi®cations such as serine phosphorylation Zhang et al., 1995) . Complex III (Stat1 homodimers) appears biphasic on both enhancers, strong at early times and again at 3 days. Myeloleukemic M1 cells which stop growing and dierentiate with IL-6, had similar long-lasting Stat3 activation and biphasic induction of complex C or III (Nakajima et al., 1996) . While most studies focused on the early Stat response around 15 min (Seidel et al., 1995; Wegenka et al., 1994; Zhong et al., 1994) , it is clear that Stat complexes can show sustained and elaborate activation such as described here with the Figure 4 Transcriptional activities induced by IL-6 and sIL-6R in F10.9 melanoma cells. The luciferase reporter genes (see Materials and methods) were transfected into F10.9 cells and 24 h later the cells were treated as indicated (IL-6, 40 ng/ml; sIL-6R, 2 mg/ml). Luminescence activity was assayed at indicated times after treatment. (a) Reporter gene pGL2-a2M with pIRE/a2M enhancer. Similar results were obtained with the pIRE/IRF-1 enhancer construct and no luciferase induction was seen when the palindromic enhancer was mutated (not shown). (b) Reporter gene WWP-Luc containing the human Waf-1/p21 gene promoter region (El-Deiry, 1993) IL-6+sIL-6R combination. These long-lasting eects may account for the profound biological changes in the F10.9 cells.
IL-6 and sIL-6R also induced a sustained 24 h increase in the IRF-1 transcription factor as well as in its DNA-binding activity. Elevation of IRF-1 is likely to have cytostatic and anti-oncogenic eects (Taniguchi et al., 1995 for review) . In cells for which IL-6 is a growth factor rather than an inhibitor (e.g. B9 plasmacytoma), the IRF-1 protein is induced but not its DNA-binding (Harroch et al., 1994a) . This seems due to IRF-2 which represses the binding and transcriptional activity of IRF-1, e.g. on IFN-b and IFN-inducible genes (Fujita et al., 1989; Pine et al., 1990; Reis et al., 1992) , as well as the cytostatic action of IRF-1 (Harada et al., 1993) . IRF-2 may itself stimulate genes involved in cell entry into S phase (Vaughan et al., 1995) . It is of interest that one form of IRF-2 was down-regulated in the F10.9 cells 3 days after treatement by IL-6 and sIL-6R.
Another candidate to mediate the growth-arrest and dierentiation eects of IL-6 and sIL-6R on F10.9 cells is p21/Waf-1/Cip-1 (El-Deiry et al., 1993; Harper et al., 1993) which inhibits cyclin-dependent kinases and entry of cells into S-phase by interfering with the dissociation of the Rb-E2F complex. The p21/Waf-1 gene is regulated by p53, and is also a tumor suppressor . Expression of p21/ Waf-1 is higher in dierentiated melanocytes than in melanomas , is high in differentiating hematopoietic cells and is induced also by p53-independent pathways (Chin et al., 1996; Jiang et al., 1994; Steinman et al., 1994) . In fact, both p53 and IRF-1 are required to fully activate the p21 gene promoter and to produce apoptosis after irradiation (Tanaka et al., 1996) . Stat1 is involved in the induction 
IL-6 IL-6+IL-6R Treatment
Figure 7 IL-6 and sIL-6R increase p21/Waf-1 protein concentration. Total proteins (20 mg) from F10.9 cells treated as in Figure 3 , were analysed on 16% SDS ± PAGE in Tris-Tricine, blotted onto nitrocellulose and reacted with anti-p21 antibodies (see Materials and methods). After recording the ECL signal, the blot was erased and reacted with hamster antibodies against the mouse bcl-2 protein (gift of Dr S Korsmeyer). The ®lms were scanned and the relative intensities of the p21/Waf-1 and of the bcl-2 signals were computed as percentage of p21/Waf-1 in cells growth-inhibited by IFN-g (Chin et al., 1996) . The activation of the p21/Waf-1 promoter by IL-6 with sIL-6R in our experiments could be mediated by several factors since the promoter segment used starts at base -2292 (El-Deiry et al., 1993) and contains a Stat-binding palindromic pIRE element (TTCCCGGAA) as well as a potential IRF-1 binding site (CAAAGTAAACA) conserved in the mouse and human genes (Tanaka et al., 1996) . Whereas p21/Waf-1 promoter activation was not seen with IL-6 alone, an increase in the p21 protein was observed (possibly post-transcriptional), albeit reaching only half of the level seen with IL-6 and sIL-6R. Thus, F10.9 cells have some response to IL-6 alone (as they are not devoid of IL-6 receptors; Katz et al., 1993a ) but this does not suce for growth-arrest and dierentiation of the cells.
Despite the in vitro resistance to IL-6 of F10.9, or other B16 melanoma cells, the in vivo injection of IL-6 did reduce metastatic tumor growth, increased mice survival and elicited antitumoral cytotoxic T-cells (Katz et al., 1993a,b) . B16 lines transfected by IL-6 genes also showed reduced tumor growth and increased tumor immunity (Mackiewicz et al., 1995b; Armstrong et al., 1994) . Although T-cell depletion reduces the antitumoral response , some eects of IL-6 transfected cells persisted in nude mice (Armstrong et al., 1994) suggesting that in addition to the immune-mediated indirect action there is also a direct eect on tumor growth. Since sIL-6R circulates in body¯uids (Gaillard et al., 1993) we now consider it possible that, in vivo, endogenous sIL-6R elicited a direct eect of IL-6 on the tumor cells. Indeed, the importance of sIL-6R for in vivo tumor suppression was seen when B16 cells transfected with sIL-6R and others with IL-6 were inoculated together (Mackiewicz et al., 1995a) .
Unmasking of anti-growth eect of IL-6 by sIL-6R addition is not unique to B16 melanoma lines, and was recently seen on human non-small cell lung carcinoma cells (Ganapathi et al., 1996) . Other tumor cells with partial growth-inhibition by IL-6 become more inhibited when sIL-6R is added, for example human melanoma A375 (Oh et al., unpublished) , human T47D breast cancer cells (Novick et al., 1992) and myeloleukemic M1 cells (Taga et al., 1989) . Screening of primary and established tumor cells for the sIL-6R eect may be of interest, even though resistance to IL-6 growth inhibition is not always overcome by sIL-6R (Silvani et al., 1995) and may be due to high IRF-2/IRF-1 ratios (Harroch et al., 1993 (Harroch et al., , 1994a . Nevertheless, considering that about 50% of advanced melanomas produce autocrine IL-6 (Colombo et al., 1992; Lu and Kerbel, 1993; Armstrong et al., 1994) , sIL-6R may enhance IL-6 eects of many tumor cells which have lost surface IL-6R due to autocrine IL-6 (Silvani et al., 1995) either by retention of IL-6R inside the cell (Rose-John et al., 1993) or by decrease in IL-6R mRNA (Ganapathi et al., 1996) . On the other hand, since the agonist eect of sIL-6R is seen also on cells with abundant IL-6 receptors (Novick et al., 1992) , the actual mechanism of the sIL-6R agonist action may well be a catalytic acceleration of gp130 dimerization within the hexameric IL-6 receptor complex Halimi et al., 1995) .
Materials and methods

Cell lines, cytokines and antibodies
Chinese Hamster Ovary (CHO) cells expressing the soluble IL-6R DVal (see below) were grown in DMEM, 200 nM Methothrexate, 150 mg/ml proline, 10% FCS. Highly metastatic F10.9 cells (Porgador et al., 1989) derived from the murine B16 melanoma were grown in DMEM supplemented with 8% FCS.
Recombinant human IL-6 (1.5610 7 U/mg) from CHO cells was a gift of Interpharm Laboratories (Ares-Serono Group, Ness-Ziona, Israel). Recombinant murine IFN gamma (5610 6 U/mg) was obtained from Genzyme (Cambridge, Ma). Neutralizing monoclonal antibodies from mouse hybridoma clone 34 (Novick et al., 1991) were a gift from Dr D Novick (Weizmann Institute, Israel). Supernatants from LIF expression vector transfected COS-7 cells were given by Dr P Lonai (Weizmann Institute, Israel). Preparation of rabbit anti IRF-1 antibodies against GST-IRF-1 fusion protein was described before (Harroch et al., 1994a) . Anti IRF-2 antibodies were prepared by injection to rabbits of GST-fused complete IRF-2 protein made in bacteria. To prepare this construct, a fragment Cfr 101-XbaI of the vector p2-5IRF (a gift of Dr Watanabe) was introduced in the SmaI site of PGEX-3X (Pharmacia).
Construction of pMSVDVal for expression of IL-6R truncated at Val 356
To produce soluble IL-6R containing most of the extracellular domain of the human gp80 IL-6R, a stop codon was introduced after the codon amino acid Val 356 of the human IL-6R cDNA. A fragment of the IL-6R cDNA was ampli®ed by PCR between forward primer A 5'-CTCAGTGTCACCTGGCAAGA (nt 1137 ± 1156; Yamasaki et al., 1988) and reverse primer B 5'-cctaagctta-CACTGGGAGGCTTGTCGC (nt 1488 ± 1505, with a tail changing the Gln 357 codon CAA into a termination codon TAA, and adding a HindIII site). The PCR fragment cut at internal EcoRV and HindIII was introduced in the pBSIL-6R vector (Oh et al., 1996) cut by EcoRV, HindIII. The XhoI fragment excised from the resulting pBSDVal and containing the 5' cDNA sequence till XhoI (nt 1762) was cloned in the XhoI site of pBEH plasmid (a gift of Dr H Hauser, GBF) in 3' of the retroviral myeloproliferative sarcoma virus (MPSV) long terminal repeat (LTR). DHFR-CHO-K1 cells were cotransfected with this plasmid along with pSVDHFR plasmid (Chernajovsky et al., 1984) . DHFR transformed clones were selected in medium plus 10% dialysed FCS. Co-ampli®cation of inserted DNA was done with 200 nM MTX. Puri®cation of recombinant receptors was done routinely by immunoanity columns on Mc Ab 34 followed by HPLC columns as described (Novick et al., 1990) or on Blue Sepharose columns followed by immunoanity puri®cation.
Assays of sIL-6R activity by transient transfection of Luciferase constructs
The double-stranded oligonucleotides pIRE/IRF-1, pIRE/ a2M, mutant 2 were cloned in the pGL2-pv vector (Promega), upstream of the enhancerless SV40 early promoter and luciferase gene as described (Harroch et al., 1994a) . Wild type Waf-1 Promoter-Luciferase (WWPLuc) plasmid (El-Deiry et al., 1993) was obtained from Dr B Vogelstein. For transfection, trypsinized F10.9 cells were incubated with DEAE Dextran and plasmids as before (Harroch et al., 1994a) . After 24 ± 30 h, IL-6 and/or recombinant sIL-6R was added to cells and Luciferase activity determined on lyzed cells using a Promega kit in a Luminometer Turner TD20e.
Colorimetric cell growth assay F10.9 cells were plated in triplicates in 96 well Nunc plates at concentrations of 2610 3 cells/well. Various concentrations of IL-6, 0 ± 80 ng/ml and sIL-6Rs, 0 ± 1 mg/well, were added to the growth medium. Four days later, the cells were ®xed in 12.5% glutardialdehyde for 30 min, washed with water, stained with 0.1% Crystal Violet for 30 min and washed again with water. The color was extracted from the samples with 10% acetic acid for 15 min and optical density was monitored at 570 nm.
DNA electrophoretic mobility shift assays (EMSA)
Cells were seeded at 10 6 cells/9 cm plate and either immediately treated for 2 to 3 days with cytokines, or alternatively treated 2 days later for 30 min to 12 hrs with cytokines. IL-6 was added at 80 ng/ml, and IL-6R at 1 mg/ ml. Treated cells were washed twice in ice-cold phosphate buered saline (PBS) and pellets frozen in liquid N 2 . Nuclear extracts (Harroch et al., 1993 (Harroch et al., , 1994a were used for EMSA performed with pIRE/IRF1, pIRE/a2M and C13 DNA probes as described before (Harroch et al., 1993 (Harroch et al., , 1994a .
Western blot analyses
Proteins (30 mg) from nuclear extracts (see EMSA) were analysed on 10% SDS ± PAGE, and electroblotted to nitrocellulose. Blocking of non-speci®c binding, was done for 2 h in PBST (0.05% Tween 20 in PBS) with 10% (w/v) dried low-fat milk. Anti-IRF antibodies (Harroch et al., 1994a) , diluted 1 : 500 in PBST with 5% milk, were added for 1 h at room temperature followed by three times 5 min washes with PBST. HRP-labeled protein-A (Amersham, UK), diluted 1 : 10 000 in same solution, was then used and peroxydase activity detected by ECL system (Amersham, UK) and exposed to ®lm. For p21/WAF-1 detection, cells were seeded on 3 cm plates (2610 6 cells for 30 min or 2 h treatment, 8610 5 cells for 24 h and 3610 5 cells for 3 days). Treatment was with 40 ng/ml IL-6 and IL-6R at 1 mg/ml. Treated cells were lyzed in PBS containing 1% Triton X-100, 1 mM PMSF, 10 mg/ml aprotinin and leupeptin, 100 mM NaF. The protein concentration was determined by the BCA protein assay (Pierce). Equal amounts (20 mg) of total cell proteins supplemented with SDS sample buer were loaded on 16% SDS gel in Tris-Tricine buer. Blotting to nitrocellulose and subsequent steps were done as above, using rabbit polyclonal IgG anti p21 (Waf-1 Ab5 from Oncogene Research Products) as the ®rst antibody.
